Infantile Hypertrophic Pyloric Stenosis (IHPS)

**Infantile Hypertrophic Pyloric Stenosis (IHPS): A Comprehensive Overview**

Infantile Hypertrophic Pyloric Stenosis (IHPS) is a condition in infants that involves abnormal thickening (hypertrophy) of the pyloric muscle, which functions as a valve between the stomach and the duodenum (the first part of the small intestine). This thickening leads to **gastric outlet obstruction**, making it difficult for food to pass from the stomach into the intestines. As a result, affected infants experience **severe, non-bilious projectile vomiting**, which progressively worsens if left untreated. IHPS is one of the most common causes of gastrointestinal obstruction in infants and requires prompt medical attention.

---

### **Epidemiology**

• **Incidence**: IHPS occurs in approximately **3 in 1,000 live births** in the United States, with variations in incidence globally (ranging from 1 to 8 in 1,000 live births).
• **Gender**: Males are 4–5 times more likely to develop IHPS compared to females.
• **Ethnicity**: The condition is most common in Caucasian infants, particularly those of Northern European descent, while it is less common in African American and Asian infants.
• **Age of Onset**: Symptoms typically appear between **3–6 weeks of age** and rarely occur after 12 weeks.
• **Familial Tendency**: IHPS often runs in families, suggesting a **polygenic inheritance pattern**. Male relatives of affected females have a particularly high risk.

---

### **Causes and Risk Factors**

The exact cause of IHPS is not fully understood, but it is believed to result from a combination of **genetic** and **environmental factors**.

#### **Genetic Factors**:

• IHPS exhibits familial clustering, indicating a genetic predisposition.
• Specific genetic loci have been identified, including **NOS1 (12q24.2)**, **IHPS2 (16p12-p13)**, and **IHPS3 (11q14-q22)**.
• Genome-wide association studies have implicated genes such as **MBNL1** and **NKX2-5** in increasing the risk of IHPS.

#### **Environmental Factors**:

• **Male sex**: Males are significantly more likely to develop IHPS.
• **Firstborn status**: Firstborn infants show a higher incidence of IHPS.
• **Macrolide antibiotics**: Exposure to macrolide antibiotics (e.g., erythromycin) during infancy or indirectly through breastfeeding increases the risk.
• **Formula feeding**: Formula-fed infants have a higher risk compared to breastfed infants.
• **Maternal factors**: Advanced maternal age, smoking during pregnancy, and bottle feeding are associated with increased risk.

---

### **Pathophysiology**

The hallmark of IHPS is **hypertrophy and hyperplasia** of the circular muscle layer of the pylorus, leading to narrowing of the pyloric canal. This narrowing causes **gastric outlet obstruction**, preventing food from moving into the small intestine.

Several hypotheses have been proposed to explain the underlying mechanisms:

1. **Nitric Oxide Deficiency**: A localized deficiency in **nitric oxide synthase**, an enzyme responsible for smooth muscle relaxation, may lead to sustained contraction of the pyloric muscle.

2. **Abnormal Neural Development**: Impaired neuronal innervation and reduced **interstitial cells of Cajal** (cells responsible for gut motility) have been implicated.

3. **Hormonal Influence**: Elevated levels of hormones such as **gastrin** and **prostaglandins** may contribute to the development of pyloric muscle hypertrophy.

---

### **Clinical Features**

IHPS typically presents with the following symptoms and signs:

1. **Projectile Vomiting**:

• Vomiting begins as mild regurgitation and progresses to **forceful, projectile vomiting** after feedings.
• Vomitus is **non-bilious**, as the obstruction occurs before the duodenum where bile enters the gastrointestinal tract.
• Occasionally, the vomitus may contain traces of blood due to irritation of the stomach lining.

2. **Feeding Difficulties**:

• Infants are often hungry after vomiting and may feed vigorously ("hungry vomiting").
• Prolonged vomiting can lead to **poor weight gain** or weight loss.

3. **Dehydration**:

• Symptoms include dry mucous membranes, sunken fontanelle, decreased urine output, and lethargy.
• Severe dehydration can lead to **failure to thrive**.

4. **Palpable "Olive" Mass**:

• A firm, mobile, olive-shaped mass may be felt in the **right upper quadrant** or **epigastrium**, representing the hypertrophied pylorus.
• This is best palpated during or immediately after feeding.

5. **Visible Peristalsis**:

• Visible peristaltic waves may be observed moving from left to right across the abdomen as the stomach attempts to push food through the obstructed pylorus.

---

### **Diagnosis**

The diagnosis of IHPS is based on **clinical findings** and **imaging studies**.

#### **Laboratory Findings**:

• **Electrolyte Imbalance**:
• **Hypochloremic metabolic alkalosis** due to the loss of hydrochloric acid from persistent vomiting.
• **Hypokalemia** due to secondary loss of potassium through the kidneys.
• **Dehydration**: Elevated blood urea nitrogen (BUN) and creatinine levels.

#### **Imaging Studies**:

1. **Ultrasound** (Gold Standard):

• Highly sensitive and specific for diagnosing IHPS.
• Key findings include:
• **Pyloric muscle thickness** >3–4 mm.
• **Pyloric channel length** >14–20 mm.
• "Target sign" or "donut sign" on transverse view of the pylorus.

2. **Upper Gastrointestinal (GI) Contrast Study**:

• Used when ultrasound results are inconclusive.
• Findings include:
• **String sign**: Narrowing of the pyloric canal.
• **Shoulder sign**: Bulging of the hypertrophied pylorus into the antrum.

---

### **Management**

The treatment of IHPS involves **preoperative stabilization** and **surgical intervention**.

#### **Preoperative Management**:

1. **Fluid and Electrolyte Replacement**:

• Intravenous (IV) fluids are administered to correct dehydration.
• Electrolyte imbalances, such as **hypochloremic metabolic alkalosis**, are treated with normal saline and potassium supplementation.

#### **Definitive Treatment**:

2. **Ramstedt Pyloromyotomy**:

• This is the standard surgical procedure for IHPS.
• A surgeon makes a longitudinal incision through the hypertrophied pyloric muscle down to the submucosa, allowing the pylorus to relax and restore normal gastric emptying.
• The procedure can be performed laparoscopically or via an open surgical approach.

#### **Postoperative Care**:

3. **Post-Surgery Feeding**:

• Feeding is resumed 12–24 hours after surgery, starting with small, frequent feeds.
• Most infants tolerate feeding well and recover quickly.

4. **Follow-Up**:

• Regular monitoring for any signs of complications, such as infection or delayed gastric emptying.

---

### **Complications**

If untreated, IHPS can lead to serious complications:

1. **Severe Dehydration**: Prolonged vomiting may result in hypovolemic shock.

2. **Electrolyte Imbalances**:

• Metabolic alkalosis can impair respiratory drive and lead to apnea.

3. **Malnutrition**: Persistent vomiting can cause failure to thrive.

4. **Gastric Perforation**: Rare but life-threatening due to increased intragastric pressure.

---

### **Differential Diagnosis**

Conditions that can mimic IHPS include:

1. **Gastroesophageal Reflux Disease (GERD)**: Vomiting is non-projectile and associated with heartburn.

2. **Pylorospasm**: A functional obstruction without hypertrophy, often resolves spontaneously.

3. **Duodenal Atresia/Stenosis**: Causes bilious vomiting due to obstruction beyond the pylorus.

4. **Malrotation with Midgut Volvulus**: Presents with bilious vomiting and requires emergency surgical intervention.

5. **Sepsis or Meningitis**: May present with vomiting, lethargy, and poor feeding.

---

### **Prognosis**

The prognosis for IHPS is excellent when diagnosed and treated promptly. After surgical intervention, most infants recover fully, resume normal feeding, and achieve healthy growth and development. Long-term complications are rare, though some infants may experience transient delayed gastric emptying or mild gastroesophageal reflux.

---

### **Key Points to Remember**

1. IHPS is a common cause of gastrointestinal obstruction in infants, typically presenting between **3–6 weeks of age**.

2. The hallmark symptom is **non-bilious projectile vomiting** and a palpable **olive-shaped mass** in the abdomen.

3. Diagnosis is confirmed via **ultrasound**, which shows thickened and elongated pyloric muscle.

4. Treatment involves **preoperative stabilization** followed by **Ramstedt pyloromyotomy**, which is highly effective.

5. Early diagnosis and treatment are crucial to prevent complications such as dehydration, malnutrition, and shock.

If you have further questions or need more details, feel free to ask!